Search

The ‘i4MDS’ consortium looks to the future at its second general meeting

Feb 29 2024 Posted in Meeting reports Tagged i4MDS

The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ‘i4MDS’—held its second general meeting in The Hague from February 9–10, 2024.

Read more

Practical information

Timelines:Application deadline: August 30, 2024 (15:00 CEST)
Notification of awards: December 2024

When & where do the meetings take place?Workshop 1:
Date: April 22-26, 2025
Venue: Cambridge, UK

CBTH session and EHA Congress:
Date: June 11-15, 2025
Venue: TBC

Workshop 2:
Date:…

Read more

EHA Research Conference 2024

Dates: March 18-21, 2024
Location: Borovets, Bulgaria
Chairs: Anna Kabanova, Martina Muckenthaler, Andreas Trumpp, Simon Haas, Jean-Emmanuel Sarry, Achille Iolascon, Britta Will and Brian Huntly

Registration is closed

EHA is proud to announce the second edition of the EHA Research Conference, titled "Molecular vulnerabilities and…

Read more

‘i4MDS’ consortium wins prestigious EHA Innovation Grant

In a significant development, the International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—known as the ‘i4MDS’— has received an esteemed EHA Innovation Grant.

Read more

EHA endorses the International COVID-19 Blood Cancer Coalition (ICBCC) Statement

On February 21, the COVID-19 Blood Cancer Coalition (ICBCC), a multi-stakeholder coalition including representatives from the global patient advocacy and clinical community, launched its Joint Patient Impact Statement and Recommendations for protecting immunocompromised blood cancer patients during the COVID-19 pandemic.

Read more

EU pilot on drug repurposing

Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.

Read more